# EA9181 (NCT04530565)

> Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

No report yet. It can be ordered.

- Drugs tested: blinatumomab plus dasatinib; blinatumomab plus ponatinib
- Indication: newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia in adults

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04530565
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: National Cancer Institute (NCI)
- Conditions: B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
- Interventions: Biospecimen Collection; Blinatumomab; Bone Marrow Aspiration and Biopsy; Cyclophosphamide; Cytarabine; Dasatinib; Dexamethasone; Doxorubicin Hydrochloride; Echocardiography Test; Electrocardiography; Lumbar Puncture; Mesna; Methotrexate; Multigated Acquisition Scan; Ponatinib Hydrochloride; Prednisone; Vincristine Sulfate
- Enrollment: 348
- Primary outcome: Overall survival (OS)

## Indexed commentary on EA9181 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 5 posts on X
- 1 YouTube video

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=ea9181-nct04530565
